

**RESEARCH ARTICLE/KLİNİK ÇALIŞMA** 

FLORA 2022;27(4):555-561 • doi: 10.5578/flora.20229604

# Back to the First Days of the Pandemic: How Well Have We Done to Diagnose COVID-19 in Healthcare Workers?

## Salgının İlk Günlerine Dönelim: Sağlık Çalışanlarında COVID-19'u Teşhis Etme Konusunda Ne Kadar Başarılı Olduk?

Ahmet SERTÇELİK<sup>1</sup>(İD), Gökhan METAN<sup>2,7</sup>(İD), Gülçin TELLİ DİZMAN<sup>2,7</sup>(İD), Duygu ATILMIŞ<sup>3</sup>(İD), Ceyda ŞAHAN<sup>4</sup>(İD), Defne KALAYCI<sup>5</sup>(İD), Alpaslan ALP<sup>6</sup>(İD), Banu ÇAKIR<sup>1</sup>(İD), Pınar ZARAKOLU<sup>2</sup>(İD), Serhat ÜNAL<sup>2,7</sup>(İD), Ömrüm UZUN<sup>2</sup>(İD)

<sup>1</sup> Division of Epidemiology, Department of Public Health, Hacettepe University Faculty of Medicine, Ankara, Türkiye

<sup>2</sup> Department of Infectious Diseases and Clinical Microbiology, Hacettepe University Faculty of Medicine, Ankara, Türkiye

<sup>3</sup> Department of Public Health, Pazarcık Health Administration, Kahramanmaraş, Türkiye

<sup>4</sup> Division of Occupational Health, Department of Public Health, Dokuz Eylül University Faculty of Medicine, İzmir, Türkiye

- <sup>5</sup> Clinic of Occupational Health, Samsun Training and Research Hospital, Samsun, Türkiye
- <sup>6</sup> Department of Medical Microbiology, Hacettepe University Faculty of Medicine, Ankara, Türkiye

<sup>7</sup> Infection Control Committee, Hacettepe University Hospitals, Ankara, Türkiye

Cite this article as: Sertçelik A, Metan G, Telli Dizman G, Atılmış D, Şahan C, Kalaycı D, et al. Back to the first days of the pandemic: How well have we done to diagnose COVID-19 in healthcare workers? FLORA 2022;27(4):555-61.

\*The results of this study were presented as an oral presentation at the 9<sup>th</sup> International Academic Platform of Infectious Diseases and Clinical Microbiology Speciality Society of Turkey, Online Congress, in May 2021.

#### ABSTRACT

**Introduction:** Healthcare workers (HCWs) are one of the most vulnerable groups for COVID-19. SARS-CoV-2 PCR was offered to HCWs who had symptoms compatible with COVID-19 or who had a close contact with COVID-19 patient. A rapid antibody test was used to identify the risk of exposure of the HCWs who worked at high-risk units in our hospital during the first month of the pandemic. Herein, we aimed to evaluate the usefulness of this approach.

**Materials and Methods:** The records of the HCWs from a university hospital who were tested by SARS-CoV-2 PCR or rapid antibody test between March 12, 2020 and April 04, 2020 were reviewed retrospectively. Demographic and clinical characteristics of HCWs were extracted from the electronic database. Wards or outpatient clinics that served COVID-19 patients were defined as high-risk units.

**Results:** A total of 599 HCWs were tested for SARS-CoV-2 by PCR and 409 by rapid antibody test. Thirty-seven (6.2%) were found to be PCR positive. Eleven (29.7%) out of 37 HCWs were asymptomatic when they were tested. There was no statistically significant relationship between PCR positivity and occupation or working unit. A positive PCR result was detected in 24 HCWs during the first admission. Eleven out of 114 HCWs who were tested by a second PCR were found to be positive and two out of 17 HCWs who were tested by a third test were reported as PCR positive. Median interval between the first and second PCR was seven days (IQR= 8.5 days) and median interval between second and third PCR test was 4.5 days for the HCWs who were reported as positive at repeated PCR tests. Rapid antibody test was positive in one HCW who did not have a history of COVID-19.

Received/Geliş Tarihi: 02/03/2022 - Accepted/Kabul Ediliş Tarihi: 21/06/2022

©Copyright 2022 by Flora. Available on-line at www.floradergisi.org.

Available Online Date: 09.12.2022

Testing for COVID-19 in Healthcare Worker

**Conclusion:** Approximately, one third of the SARS-CoV-2 PCR positive HCWs were asymptomatic. In case of increasing incidence of COVID-19 in the community, a regular screening policy for the HCWs regardless of their occupation and contact tracing might help to have a safe environment in hospitals. Screening policy should be based on well validated tests.

Key Words: Healthcare personnel; COVID-19; SaRS-CoV-2 antibody testing; COVID-19 nucleic acid testi; Contact tracing

## ÖΖ

## Salgının İlk Günlerine Dönelim: Sağlık Çalışanlarında COVID-19'u Teşhis Etme Konusunda Ne Kadar Başarılı Olduk?

Ahmet SERTÇELİK<sup>1</sup>, Gökhan METAN<sup>2,7</sup>, Gülçin TELLİ DİZMAN<sup>2,7</sup>, Duygu ATILMIŞ<sup>3</sup>, Ceyda ŞAHAN<sup>4</sup>, Defne KALAYCI<sup>5</sup>, Alpaslan ALP<sup>6</sup>, Banu ÇAKIR<sup>1</sup>, Pınar ZARAKOLU<sup>2</sup>, Serhat ÜNAL<sup>2,7</sup>, Ömrüm UZUN<sup>2</sup>

<sup>1</sup> Hacettepe Üniversitesi Tıp Fakültesi, Halk Sağlığı Anabilim Dalı, Epidemiyoloji Bilim Dalı, Ankara, Türkiye

<sup>2</sup> Hacettepe Üniversitesi Tıp Fakültesi, İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı, Ankara, Türkiye

<sup>3</sup> Pazarcık Sağlık Müdürlüğü, Halk Sağlığı Daire Başkanlığı, İş ve Meslek Hastalıkları Bilim Dalı, Kahramanmaraş, Türkiye

<sup>4</sup> Dokuz Eylül Üniversitesi Tıp Fakültesi, Halk Sağlığı Anabilim Dalı, İş ve Meslek Hastalıkları Kliniği, İzmir, Türkiye

<sup>5</sup> Samsun Eğitim ve Araştırma Hastanesi, İş Sağlığı Kliniği, Samsun, Türkiye

<sup>6</sup> Hacettepe Üniversitesi Tıp Fakültesi, Tıbbi Mikrobiyoloji Anabilim Dalı, Ankara, Türkiye

<sup>7</sup> Hacettepe Üniversitesi Hastaneleri, İnfeksiyon Kontrol Komitesi, Ankara, Türkiye

*Giriş:* Sağlık çalışanları Koronavirüs Hastalığı 2019 (COVID-19) için en duyarlı gruplardan biridir. COVID-19 ile uyumlu belirtileri olan ve COVID-19 hastalarıyla yakın temas öyküsü olan sağlık çalışanlarına SARS-CoV-2 polimeraz zincir reaksiyonu (PCR) testi yapılması önerilmektedir. Hastanemizde pandeminin ilk ayında yüksek riskli birimlerde çalışan sağlık çalışanlarına SARS-CoV-2'ye maruziyet riskini değerlendirmek amacı bir hızlı antikor testi uygulanmıştır. Bu araştırma bu yaklaşımın kullanışlı olup olmadığının değerlendirilmesi için yapılmıştır.

Materyal ve Metod: Ankara, Türkiye'den bir üniversite hastanesinde 12 Mart ve 04 Nisan 2020 tarihleri arasında SARS-CoV-2 PCR veya hızlı antikor testi ile test edilen sağlık çalışanlarının bilgileri geriye dönük olarak taranmıştır. Sağlık çalışanlarının demografik ve klinik özellikleri elektronik sistemden çekilmiştir. COVID-19 hastalarına hizmet veren poliklinik ve yatan hasta servisleri yüksek riskli birimler olarak sınıflandırılmıştır.

**Bulgular:** Sağlık çalışanlarının 599'una SARS-CoV-2 PCR ve 409'una hızlı antikor testi uygulandı. Otuz yedi (%6.2) sağlık çalışanı PCR pozitif olarak bulundu. Otuz yedi sağlık çalışanından 11'i (%29.7) test edildiği sırada belirtisizdi. PCR pozitifliği ile meslek ve çalışılan birim arasında istatistiksel olarak anlamlı bir ilişki saptanmadı. Yirmi dört sağlık çalışanının ilk başvurusu sırasında PCR testi pozitif sonuçlandı. İkinci kez PCR testi yapılan 114 sağlık çalışanının 11'i, üçüncü kez PCR testi yapılan 17 sağlık çalışanının ikisi pozitif olarak bildirildi. Tekrarlayan PCR testlerinde pozitiflik bildirilen sağlık çalışanlarında birinci ve ikinci PCR testi arasındaki ortanca süre yedi gün (ÇADA= 8.5 gün), ikinci ve üçüncü PCR testi arasındaki ortanca süre 4.5 gündü. Hızlı antikor testi COVID-19 öyküsü olmayan bir sağlık çalışanında pozitif sonuçlandı.

**Sonuç:** SARS-CoV-2 PCR pozitif sağlık çalışanlarının yaklaşık üçte biri asemptomatikti. Toplumda COVID-19 insidansının arttığı bir durumda sağlık çalışanları için mesleklerinden bağımsız olarak düzenli bir tarama politikası ve temaslı takibi hastanelerde güvenli bir ortam oluşturulmasında yardımcı olacaktır. Tarama politikası geçerliliği iyi gösterilmiş testlere dayanmalıdır.

Anahtar Kelimeler: Sağlık çalışanı; COVID-19; SaRS-CoV-2 antikor testi; COVID-19 nükleik asit testi; Temaslı izlemi

## **INTRODUCTION**

The first confirmed Coronavirus disease 2019 (COVID-19) case was identified in Türkiye on March 10, 2020, one day before the World Health Organization (WHO) announced COVID-19 as a pandemic<sup>[1,2]</sup>. Healthcare workers (HCWs) are the most vulnerable group for COVID-19 as front-line fighters. The high rate of severe acute

respiratory syndrome coronavirus-2 (SARS-CoV-2) infected HCWs is of concern. Turkish Minister of Health announced that 29.865 out of 273.000 patients diagnosed as COVID-19 were HCWs by September,  $2020^{[3]}$ .

The first COVID-19 patients were two housemate residents from the department of internal medicine in our hospital, diagnosed on March 20, 2020<sup>[4]</sup>. We decided to develop a strategy to detect COVID-19 in HCWs as early as possible. This strategy included polymerase-chain-reaction (PCR) based testing of HCWs with clinical symptoms consistent with COVID-19 or in case of close contact with a COVID-19 patient without appropriate use of personal protective equipment (PPE). A rapid antibody test was offered to HCWs without symptoms from high-risk units who took care of COVID-19 patients as a screening test to investigate SARS-CoV-2 exposure. In this study, it was aimed to the share the utility of this approach for the diagnosis of COVID-19 in HCWs during the first month of the pandemic in Türkiye.

## MATERIALS and METHODS

Hacettepe University Hospital University Hospital is a tertiary care hospital in Ankara, Türkiye. HCWs with signs and symptoms of a respiratory infection were admitted to COVID-19 initial evaluation outpatient clinic (C1) organized by the department of infectious diseases, whereas those who had contact with a COVID-19 patient but did not have any symptoms were evaluated at the occupational health clinic (OHC) and then referred to C1 for PCR testing when necessary. A combined oropharyngeal and nasopharyngeal swab was taken from HCWs to detect SARS-CoV-2 by real-time reverse-transcriptase-polymerase-chain-reaction (RT-PCR). Viral nucleic acid isolation from the samples was achieved by using Bio-Speedy vNAT viral nucleic acid buffer (Bioeksen R&D Technologies Ltd, Türkiye). COVID-19 real-time PCR kit (Bioeksen R&D Technologies Ltd, Türkiye) was used for diagnosis in our hospital.

А CE (Conformité Européenne) certified immunochromatographic test named as Hotgen COVID-19 IgM/IgG Antibody Rapid Test (Beijing Hotgen Biotech Co, Ltd, China) was used to investigate the exposure of HCWs to SARS-CoV-2. Hotgen can detect both IgM and IgG against SARS-CoV-2 in human serum by using double antigen sandwich technology in 15 minutes according to the manufacturer's manual (http://www.hotgen.com.cn/ky/upt.html). This test kit was provided free of charge by the Turkish Ministry of Health. Priority for testing by Hotgen was given to the HCWs from high-risk units such as C1, intensive care units, wards caring for COVID-19 patients, as well as emergency ward.

All laboratory records were reviewed to identify the HCWs who were tested either by SARS-CoV-2 PCR or Hotgen between March 20, 2020 and April 09, 2020, retrospectively. Demographic and clinical characteristics of HCWs such as sex, age, occupation, presence of any symptom and history of contact with COVID-19 patient were extracted from the hospital database.

For descriptive statistics, continuous variables were given as mean ± standard deviation for normally distributed data, and as median and range (IQR) data interguartile for with the non-normal distribution. Categorical variables were reported as numbers and percentage distributions. Categorical variables were compared by Chi-Square test or Fischer's exact test, and continuous variables were compared by the independent-samples t test for normally distributed data or Mann-Whitney U test for non-normally distributed data. The odds ratios (OR) and their confidence interval (CI) 95% were calculated to give potential association as an effect size value. Type 1 error probabilities were accepted as 0.05 for all statistical tests. Statistical analyses were performed with Statistical Package for the Social Sciences (SPSS) version 23 software (IBM SPSS<sup>®</sup>, Armonk, New York, USA).

This study was approved by the Hacettepe University Non-interventional Clinical Researches Ethics Committee (Approval date: 22.05.2020, Number: 2020/10-40).

## RESULTS

A total of 599 HCWs were tested for SARS-CoV-2 by PCR and 409 by Hotgen between March 12, 2020 and April 09, 2020. One hundred and forty-six HCWs were tested by both PCR and Hotgen at different time points.

Mean age of the HCWs tested by PCR was  $34.5 \pm 9.0$  years. Three hundred and fifty-one (58.5%) were females. Physicians (n= 240, 40.1%) and nurses (n= 189, 31.6) were the most common HCWs who were tested by PCR.

Thirty-seven (6.2%) of 599 HCWs were found to be PCR positive. A positive PCR result was detected in 24 HCWs during the first admission. Eleven out of 114 HCWs who were tested by a second PCR were found to be positive, and two out of 17 HCWs who were tested by a third test were reported as PCR positive. Median interval between the first and second PCR was seven days (IQR= 8.5 days) and median interval between second and third PCR test was 4.5 days for the HCWs who were reported as positive at repeated PCR tests. Admission with any respiratory symptoms (OR= 8.26; p< 0.001), fever (OR= 6.13; p< 0.001), and pneumonia (OR= 7.16; p= 0.002) was more common in HCWs with a positive PCR. There was no statistically significant difference regarding the occupation and working unit (high vs low-risk) between PCR positive and PCR negative HCWs (Table 1). There were no deaths among HCWs during the study period.

Table 1. Descriptive characteristics of the healthcare workers tested by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) polymerase chain reaction (PCR)

|                                                                                                                                                                                                             | PCR Positive<br>n (%) | PCR Negative<br>n (%) | Odds Ratio<br>(Confidence Interval<br>95%) | р       |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|-----------------------|--------------------------------------------|---------|
| Female                                                                                                                                                                                                      | 24 (64.9)             | 327 (58.2)            | 1.32 (0.66-2.66)                           | 0.42    |
| Any symptom                                                                                                                                                                                                 | 26 (70.3)             | 125 (22.2)            | 8.26 (3.97-17.19)                          | < 0.001 |
| Fever                                                                                                                                                                                                       | 10 (27.0)             | 32 (5.7)              | 6.13 (2.73-13.77)                          | < 0.001 |
| Pneumonia                                                                                                                                                                                                   | 5 (13.5)              | 12 (2.1)              | 7.16 (2.38-21.57)                          | 0.002   |
| Contact history                                                                                                                                                                                             | 32 (89.2)             | 461 (82.0)            | 1.81 (0.63-5.22)                           | 0.26    |
| Symptomatic + contact history                                                                                                                                                                               | 18 (48.6)             | 66 (11.7)             | 7.12 (3.56-14.25)                          | <0.001  |
| Occupation                                                                                                                                                                                                  |                       |                       |                                            |         |
| Physicians (n= 240)<br>Nurses (n= 189)                                                                                                                                                                      | 26 (70.3)             | 403 (71.7)            |                                            |         |
| The other healthcare workers<br>Housekeeping staff (n= 81)<br>Food servers (n= 44)<br>Secretaries (n= 13)<br>Transport staffs (n= 17)<br>Echnical staffs (n= 7)<br>The other workers (n= 8)<br>Working Unit | 11 (29.7)             | 159 (28.3)            | 0.93 (0.45-1.93)                           | 0.85    |
| High risk units                                                                                                                                                                                             | 17 (45.9)             | 179 (33.6)            | 1.68 (0.86-3.28)                           | 0.13    |
| Other units                                                                                                                                                                                                 | 20 (54.1)             | 353 (66.4)            | 1.00 (0.00-5.20)                           | 0.15    |
|                                                                                                                                                                                                             | Median<br>(IQR)       | Median<br>(IQR)       | Z                                          | р       |
| Age (years) (n= 862)                                                                                                                                                                                        | 31.0 (17)             | 33 (12)               | 0.12                                       | 0.99    |
| Interval of the first and second PCR (days)<br>(n= 114)                                                                                                                                                     | 7 (8.5)               | 8 (12.5)              | 0.61                                       | 0.59    |
| Interval of the second and third PCR (days)<br>(n= 17)                                                                                                                                                      | 4.5 (-)               | 5 (6)                 | 0.58                                       | 0.88    |
| Interval of the first symptoms and PCR (days)<br>(n= 141)                                                                                                                                                   | 2 (1)                 | 0 (2)                 | 2.37                                       | 0.01    |

Mean age of the HCWs tested by rapid antibody test was 34.2 ± 8.5 years and 228 (55.7) were female. Physicians (n = 127, 31.1%) and nurses (n= 153, 37.4%), and housekeeping staff (n= 96, 23.5%) were the most frequently tested HCWs by rapid antibody test. Two hundred and seventy-eight (73.0%) of 409 HCWs tested by rapid antibody test were working at high-risk units. Twenty (4.9%) of the healthcare workers tested with the rapid antibody test were symptomatic, and they were also tested with PCR. Two (0.5%) out of 409 HCWs were detected positive by rapid antibody test. One of these HCWs was diagnosed with COVID-19 pneumonia by PCR and positive chest scan, previously. SARS-CoV-2 PCR was performed just after the positive rapid antibody test result, and it was negative in the other HCW.

## DISCUSSION

Approximately 5.600 HCWs work at Hacettepe University Hospitals. During the first 20 days of the pandemic in Türkiye, we tested nearly 10%of our HCWs. The testing strategy identified COVID-19 in 26 symptomatic HCWs, in 11 asymptomatic HCWs, and previous exposure to SARS-CoV-2 in one HCW. The rate of SARS-CoV-2 PCR positive HCWs in high-risk units and other clinics were similar in our study. While a study from Wuhan has reported that HCWs serving at high-risk clinics such as infectious diseases, respiratory diseases and intensive care units had 2.13-fold increased risk of getting COVID-19, a study from England has shown that COVID-19 rates were not different in hospital staff regarding the working unit or patient care<sup>[5,6]</sup>. Those findings underline the impact of a regular screening policy not only for the HCWs from high-risk units but also for the HCWs working at other services of the hospital particularly during high COVID-19 burden in the community.

Asymptomatic or pre-symptomatic HCWs can serve as an important source for the rapid spread of COVID-19 in the hospital setting. Approximately one-third (29.7%) of the PCR positive HCWs were asymptomatic in our analysis. A study from Saudi Arabia has reported that 62.8% of HCWs who were found to be seropositive for SARS-CoV-2 antibodies did not

have any symptoms<sup>[7]</sup>. The rate of SARS-CoV-2 IgG positivity was 7.4% in 774 HCWs who were screened by Enzyme-Linked Immunosorbent Assav (ELISA) in our hospital, and only 3.5% of SARS-CoV-2 IgG positive HCWs were not previously diagnosed as COVID-19<sup>[8]</sup>. This finding shows that our policy as "low-threshold testing for HCWs with any respiratory symptom" seems to be successful. However, there were 16 HCWs with a positive SARS-CoV-2 PCR who were cumulated in three wards. Surgical mask became mandatory on March 30 at our hospital. In the absence of mandatory mask usage and low compliance to social distance until the detection of cumulation of SARS-CoV-2 infected HCWs, it is probable that the testing strategy that was based on symptoms and contact history did not allow to identify all infected HCWs immediately.

There is still a controversy about screening asymptomatic HCWs by PCR. Asymptomatic HCW ratio has been reported as 34% in a maternity and child hospital from London<sup>[9]</sup>. However, a proactive surveillance system for HCWs by summoning with text messages periodically has resulted in the diagnosis of 43 (0.9%)out of 4896 employees in Israel, and only five (11.6%) out of 43 were asymptomatic<sup>[10]</sup>. This situation can become more complex after the removal of mandatory mask use in vaccinated HCWs with mild symptoms. Thirty-nine of 62 HCWs diagnosed with COVID-19 infection were fully vaccinated by CoronaVac (Sinovac Life Sciences, Beijing, China) in a Turkish University Hospital<sup>[11]</sup>, and all had mild symptoms. A decline in antibody levels has just been recently reported for HCWs who received two doses mRNA of BNT162b2 (Pfizer-BionTech) after three months<sup>[12]</sup>. In addition to immune waning, vaccine hesitancy is still of concern in HCWs<sup>[13,14]</sup>. Moreover, a recent study has shown that there was no difference between vaccinated and unvaccinated patients regarding secondary attack rates during the last COVID-19 wave by Omicron variant in Spain. The authors have reported that half of Omicron contagion events happened before symptom onset<sup>[15]</sup>. All of these problems underline the impact of a vigorous screening program for unvaccinated HCWs, as well as healthcare providers who are at risk for immune waning after vaccination.

Limiting PCR testing in symptomatic patients or close contacts of COVID-19 patients during the surge of COVID-19 can result in the missing of asymptomatic HCWs with potential of transmission of SARS-CoV-2. However, there are several problems for regular screening by PCR. Obtaining a nasopharyngeal swab can be risky if proper PPE is not used or it is performed in a poorly ventilated area. It is not easy to arrange such an area and staff sampling for asymptomatic HCWs at hospital with a high number of COVID-19 admissions. Moreover, nasopharyngeal sampling can become a disturbing intervention when performed once or twice a week, so asymptomatic HCWs might avoid testing. Recent studies have shown that saliva is a promising sample to test for SARS-CoV-2 by PCR, and pooled analysis of saliva samples from nursing homes and schools resulted in decrease of COVID-19 infection ratio<sup>[16-18]</sup>. As another approach, self-collected gargle-samples were successfully used for PCR to screen asymptomatic 7513 HCWs with a sensitivity of 88.9% and a specificity of  $99.8\%^{[19]}$ .

During the early phase of the pandemic in Türkiye, ELISA based tests were not available. We detected only one HCW with positive antibody test who did not have any history of COVID-19. Since we did not have any comparative test, it was difficult to assess the performance of this test. Seven of 25 patients who had thoracic computed tomography findings compatible with COVID-19 had a positive test result with Hotgen that was performed 3-5 days after the second negative RT-PCR test results<sup>[20]</sup>. The consistency between Hotgen and Roche SARS-CoV-2 assay was reported as 70.3% for SARS-CoV-2 PCR positive patients (n= 31) and 100% for SARS-CoV-2 PCR negative patients<sup>[21]</sup>. Several limitations such as false negative or false positive results of rapid antibody tests in the early phase of the pandemic have been already reported<sup>[22]</sup>. The sensitivity of rapid antibody tests produced in China detecting both IgG and IgM varies between 11-100%. The performance of the tests is influenced by severity of the disease and testing days from disease onset<sup>[23]</sup>. More studies are needed to understand the performance of rapid antibody tests to investigate the risk of SARS-CoV-2 exposure in healthcare settings.

COVID-19 pandemic will not disappear in a short time. In case of increasing incidence of COVID-19 in the community, screening HCWs by a validated test regardless of occupation and contact history appears to be essential for a safe environment in hospitals. This might be particularly useful in settings where vaccination coverage and/or mask use compliance is limited with a high rate of COVID-19 in the community.

## Acknowledgments

We would like to thank all healthcare workers for their devoted work during the pandemic.

#### ETHICS COMMITTEE APPROVAL

This study was approved Hacettepe University Non-invasive Clinical Research Ethics Committee (Decision no: 2020/10-05, Date: 20.05.2020).

## CONFLICT of INTEREST

None of the authors had conflict of interest.

## AUTHORSHIP CONTRIBUTIONS

Concept and Design: GM

Analysis/Interpretation: AS, GM, BC

Data Collection or Processing: DA, GM, GTD, AA, PZ, SÜ, ÖU, CS, DK

Writing: AS, GM, OU

Review and Correction: All of authors

Final Approval: All of authors

## REFERENCES

- Anadolu Ajansı (AA). Sağlık Bakanı Koca Türkiye'de ilk koronavirüs vakasının görüldüğünü açıkladı. Available from: https://www.aa.com.tr/tr/koronavirus/saglik-bakani-koca-turkiyede-ilk-koronavirus-vakasinin-goruldugunu-acikladi/1761466. (Accessed date: 13.06.2021)
- WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. World Health Organisation. Available from: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-themedia-briefing-on-covid-19---11-march-2020 (Accessed date: 13.06.2021)
- COVID-19 Hastalığına Yakalanmış Sağlık Çalışanları. Türk Tabipleri Birliği. Available from: https://www.ttb.org.tr/ kutuphane/covid19-rapor\_6/covid19-rapor\_6\_Part35.pdf (Accessed date: 20.10.2020)

- Uyaroğlu OA, Başaran NÇ, Özışık L, Taş Z, Telli Dizman G, İnkaya AÇ, et al. First confirmed cases of 2019 novel coronavirus in a university hospital in Turkey: Housemate internists. Acta Medica 2021;52(1):75-81. https://doi. org/10.32552/2020.ActaMedica.476
- Ran L, Chen X, Wang Y, Wu W, Zhang L, Tan X. Risk factors of healthcare workers with coronavirus disease 2019: A retrospective cohort study in a designated hospital of Wuhan in China. Clin Infect Dis 2020;71(16):2218-21. https:// doi.org/10.1093/cid/ciaa287
- HunterE, PriceDA, MurphyE, vanderLoeffIS, BakerKF, Lendrem D, et al. First experience of COVID-19 screening of health-care workers in England. Lancet 2020;395(10234):e77-e78. https://doi.org/10.1016/S0140-6736(20)30970-3
- Alhabbab RY, Alsaieedi A, Algaissi A, Almahboub S, Al-Raddadi RM, Shabouni OI, et al. Seroprevalence of SARS-CoV-2 binding and neutralizing antibodies in healthcare workers during the epidemic peak in referral hospitals and quarantine sites: Saudi Arabia. Viruses 2021;13(7):1413. https:// doi.org/10.3390/v13071413
- Özdemir A, Demir Çuha M, Telli Dizman G, Alp A, Metan G, Şener B. SARS-CoV-2 seroprevalence among healthcare workers: Retrospective analysis of the data from a university hospital in Turkey. Mikrobiyol Bul 2021;55(2):223-32. https://doi.org/10.5578/mb.20219908
- Khalil A, Hill R, Ladhani S, Pattisson K, O'Brien P. CO-VID-19 screening of health-care workers in a London maternity hospital. Lancet Infect Dis 2021;21(1):23-24. https://doi.org/10.1016/S1473-3099(20)30403-5
- Oster Y, Wolf DG, Olshtain-Pops K, Rotstein Z, Schwartz C, Benenson S. Proactive screening approach for SARS-CoV-2 among healthcare workers. Clin Microbiol Infect 2021;27(1):155-6. https://doi.org/10.1016/j. cmi.2020.08.009
- 11. Özlem A-K, Hande A, Erol Ç, Yanık-Yalçın T, Sarı N. Healthcare workers should be inoculated with the highest effective vaccine available. Infect Dis and Clin Microbiol 2021;3(2):107-108. https://doi.org/10.36519/ idcm.2021.47
- Erice A, Varillas-Delgado D, Caballero C. Decline of antibody titres 3 months after two doses of BNT162b2 in non-immunocompromised adults. Clin Microbiol Infect 2021;28(1):139.e1-139.e4. https://doi.org/10.1016/j. cmi.2021.08.023
- Yılmaz S, Çolak FU, Yılmaz E, Ak R, Hokenek NM, Altıntaş MM. Vaccine hesitancy of health-care workers: Another challenge in the fight against COVID-19 in Istanbul. Disaster Med Public Health Prep 2021:1-7. https://doi. org/10.1017/dmp.2021.257
- 14. Yurttaş B, Poyraz BC, Süt N, Özdede A, Öztaş M, Uğurlu S, et al. Willingness to get the COVID-19 vaccine among patients with rheumatic diseases, healthcare workers and general population in Turkey: A web-based survey. Rheumatol Int 2021;41(6):1105-14. https://doi.org/10.1007/s00296-021-04841-3

- Del Aguila-Mejia J, Wallmann R, Calvo-Montes J, Rodriguez-Lozano J, Valle-Madrazo T, Aginagalde-Llorente A. Secondary attack rate, transmission and incubation periods, and serial interval of SARS-CoV-2 Omicron variant, Spain. Emerg Infect Dis 2022;28(6):1224-8. https://doi.org/10.3201/eid2806.220158
- Kivela JM, Jarva H, Lappalainen M, Kurkela S. Saliva-based testing for diagnosis of SARS-CoV-2 infection: A meta-analysis. J Med Virol 2021;93(3):1256-8. https://doi. org/10.1002/jmv.26613
- 17. Saegerman C, Donneau AF, Speybroeck N, Diep AN, Williams A, Stamatakis L, et al. Repetitive saliva-based mass screening as a tool for controlling SARS-CoV-2 transmission in nursing homes. Transbound Emerg Dis 2022;69(4):e194-e203. https://doi.org/10.1111/ tbed.14280
- Mendoza RP, Bi C, Cheng HT, Gabutan E, Pagaspas GJ, Khan N, et al. Implementation of a pooled surveillance testing program for asymptomatic SARS-CoV-2 infections in K-12 schools and universities. EClinicalMedicine 2021;38:101028. https://doi.org/10.1016/j. eclinm.2021.101028
- Olearo F, Norz D, Hoffman A, Grunwald M, Gatzemeyer K, Christner M, et al. Clinical performance and accuracy of a qPCR-based SARS-CoV-2 mass-screening workflow for healthcare-worker surveillance using pooled self-sampled gargling solutions: A cross-sectional study. J Infect 2021;83(5):589-93. https://doi.org/10.1016/j. jinf.2021.08.047
- Çalık Başaran N, Uyaroğlu OA, Telli Dizman G, et al. Outcome of noncritical COVID-19 patients with early hospitalization and early antiviral treatment outside the ICU. Turk J Med Sci 2021;51(2):411-20. https://doi.org/10.3906/ sag-2006-173
- Aslan O, Mızraklı A, Aktar GS, Onur AR. Evaluation of anti-SARS-CoV-2 antibody levels: two different methods. Rev Assoc Med Bras (1992) 2021;67(4):597-601. https://doi. org/10.1590/1806-9282.20201165
- Singh S. Rapid antibody-based tests for the diagnosis of COVID-19: A bigger epidemic of unscientific practices. J Lab Physicians Mar 2020;12(1):1-2. https://doi.org/10.1055/s-0040-1712711
- Ejazi SA, Ghosh S, Ali N. Antibody detection assays for COVID-19 diagnosis: An early overview. Immunol Cell Biol 2021;99(1):21-33. https://doi.org/10.1111/imcb.12397

#### Address for Correspondence/Yazışma Adresi

Dr. Ahmet SERTÇELİK

Hacettepe University Faculty of Medicine, Department of Public Health, Division of Epidemiology, Ankara-Türkiye E-posta: ahmetsertcelik@gmail.com